About brainsway ltd - BWAY
Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut in 2003 and is headquartered in Jerusalem, Israel.
BWAY At a Glance
Brainsway Ltd.
Bynet Building
Jerusalem, Jerusalem 9777518
| Phone | 972-2-582-4030 | Revenue | 52.64M | |
| Industry | Medical Specialties | Net Income | 7.64M | |
| Sector | Health Technology | 2025 Sales Growth | 27.732% | |
| Fiscal Year-end | 12 / 2026 | Employees | 129 | |
| View SEC Filings |
BWAY Valuation
| P/E Current | 58.755 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 47.337 |
| Price to Sales Ratio | 7.155 |
| Price to Book Ratio | 5.091 |
| Price to Cash Flow Ratio | 21.37 |
| Enterprise Value to EBITDA | 53.167 |
| Enterprise Value to Sales | 5.967 |
| Total Debt to Enterprise Value | 0.022 |
BWAY Efficiency
| Revenue/Employee | 408,056.589 |
| Income Per Employee | 59,186.762 |
| Receivables Turnover | 12.805 |
| Total Asset Turnover | 0.507 |
BWAY Liquidity
| Current Ratio | 3.726 |
| Quick Ratio | 3.436 |
| Cash Ratio | 3.084 |
BWAY Profitability
| Gross Margin | 74.135 |
| Operating Margin | 8.278 |
| Pretax Margin | 14.763 |
| Net Margin | 14.505 |
| Return on Assets | 7.359 |
| Return on Equity | 11.272 |
| Return on Total Capital | 9.546 |
| Return on Invested Capital | 10.458 |
BWAY Capital Structure
| Total Debt to Total Equity | 9.318 |
| Total Debt to Total Capital | 8.523 |
| Total Debt to Total Assets | 6.023 |
| Long-Term Debt to Equity | 7.848 |
| Long-Term Debt to Total Capital | 7.179 |